Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Mesothelin is a cell surface protein that is overexpressed in numerous cancers, including breast, ovarian, lung, liver, and pancreatic tumors. Aberrant expression of mesothelin has been shown to promote tumor progression and metastasis through interaction with established tumor biomarker CA125. Ther...
Main Authors: | Allison R Sirois, Daniela A Deny, Samantha R Baierl, Katia S George, Sarah J Moore |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5940182?pdf=render |
Similar Items
-
Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
by: Takahiro Einama, et al.
Published: (2017-10-01) -
Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
by: Joshua R. Faust, et al.
Published: (2022-03-01) -
Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis
by: KRISTIAN MADEIRA, et al.
Published: (2016-06-01) -
The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
by: Yu Yi, et al.
Published: (2011-07-01) -
Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
by: Xianyu Zhang, et al.
Published: (2022-07-01)